Key facts
- It has raised $108.0M across 3 recorded rounds; the latest was Early Stage VC ($5.0M) in Jan 2025.
- Notable investors include RA Capital Management, Citadel Enterprise Americas, AbbVie Ventures, Blackwell Partners, Curie.Bio — 13 tracked in total.
- Ambagon Therapeutics has filed 6 Form Ds with the SEC since 2020, most recently Feb 2025 ($5.0M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Ambagon Therapeutics
Funding rounds
3 roundsAbout Ambagon Therapeutics
Developer of small-molecule cancer drugs designed to stabilize the direct interaction of oncogenic proteins. The company's drugs selectively augment the endogenous tumor suppression activity of proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches, thereby enabling physicians to address other major unmet clinical needs.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Eindhoven, Netherlands
- Founded
- 2019
- Employees
- 17
- Website
- ambagontx.com/
- Ownership
- Privately Held (backing)
Ambagon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ambagon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ambagon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.